Examining the protective effects of gastrodin on heart injury during cardiac surgery
Study on the Protective Effect of Gastrodin on Myocardial Injury in Patients Undergoing Cardiac Surgery
This study is testing if gastrodin can help protect the hearts of patients with hypertrophic cardiomyopathy during cardiac surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Wuhan Union Hospital, China Academic / other |
| Locations | 1 site (Wuhan, Hubei) |
| Trial ID | NCT06012968 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with hypertrophic cardiomyopathy who are undergoing cardiac surgery. Participants are divided into two groups: one receiving gastrodin and the other serving as a control. Myocardial tissue samples will be collected to assess cell damage, and postoperative clinical outcomes will be monitored and compared between the two groups. The goal is to analyze the potential protective effects of gastrodin on myocardial injury during surgery.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old with hypertrophic cardiomyopathy scheduled for elective surgery.
Not a fit: Patients with severe underlying conditions or serious genetic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved postoperative outcomes for patients undergoing cardiac surgery.
How similar studies have performed: While similar studies on myocardial protection exist, the specific use of gastrodin in this context is less explored, making this approach somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with hypertrophic cardiomyopathy aged≥18 years, regardless of gender; * Patients undergoing elective hypertrophic cardiomyopathy outflow tract surgery; * Signed informed consent, good compliance. Exclusion Criteria: * suffering from more serious genetic diseases (such as immunodeficiency, thalassemia, etc.); * moderate to severe malnutrition, moderate to severe anemia; * persistent infection; * severe preoperative underlying diseases (such as severe liver and kidney dysfunction)
Where this trial is running
Wuhan, Hubei
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China (Recruiting)
Study contacts
- Study coordinator: Qingping Wu, doctor
- Email: wqp1968@126.com
- Phone: 13971605283
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.